Benitec Biopharma sees positive results in gene therapy treatment for muscular dystrophy patients

From GlobeNewswire: 2024-10-12 06:30:00

Benitec Biopharma Inc. announced positive results in the treatment of dysphagia with BB-301 gene therapy for Oculopharyngeal Muscular Dystrophy. Subjects 1 and 2 experienced significant improvements in swallowing post-treatment, with Subject 2 achieving a clinically normal swallowing profile. A conference call to discuss interim results will be held on October 14 at 8:30 am EDT. These results mark the first successful improvements in swallow function using gene therapy for OPMD, a rare muscle-wasting disease. BB-301 utilizes a unique silence and replace mechanism to target mutant genes and provide functional replacement proteins.’https://www.globenewswire.com/en/news-release/2024/10/12/2315403/0/en/Benitec-Biopharma-Provides-Interim-BB-301-Gene-Therapy-Clinical-Trial-Update.html’



Read more at GlobeNewswire: Benitec Biopharma Reports Positive Data from Two Subjects